Health Economics Methods and Quantitative Analysis
Health economics methods and quantitative analysis is the methodological core of health economics: the set of techniques used to measure the costs and consequences of health interventions and to inform decisions about how scarce health-care resources should be used. It brings together economic evaluation (such as cost-effectiveness and cost-utility analysis), decision-analytic and simulation modelling, costing methods, and the analysis of uncertainty, all organised around the central economic idea of opportunity cost.
Definition
Health economics methods are the quantitative procedures—economic evaluation, decision modelling, costing, and uncertainty analysis—by which the costs and health outcomes of competing options are estimated and compared to support resource-allocation decisions under a budget constraint.
Scope
This area orients the reader to the quantitative toolkit of health economics rather than to any single technique. It groups four topic clusters: economic modelling and simulation, budget constraints and optimisation, cost data collection and valuation, and sensitivity analysis in economic evaluation. It treats these as methodological reference material that describes how economic evidence is generated and appraised, not as clinical or purchasing guidance.
Sub-topics
Core questions
- How are the costs and health consequences of competing interventions measured and compared?
- How is uncertainty in costs, effects, and model structure quantified and reported?
- How does the opportunity cost of spending on one intervention enter the analysis when budgets are fixed?
- What standards govern the conduct and transparent reporting of an economic evaluation?
Key concepts
- Opportunity cost
- Cost-effectiveness and cost-utility analysis
- Incremental cost-effectiveness ratio (ICER)
- Decision-analytic and simulation modelling
- Costing and resource-use valuation
- Deterministic and probabilistic sensitivity analysis
- Cost-effectiveness threshold
- Perspective and time horizon
Mechanisms
An economic analysis links resource use and health outcomes for each option being compared. Costs are identified, measured, and valued; outcomes are expressed in natural units or in preference-based measures such as quality-adjusted life years; and the two are combined, typically as an incremental cost-effectiveness ratio that expresses extra cost per unit of extra health. Decision-analytic models synthesise evidence from many sources over an appropriate time horizon, and sensitivity analysis propagates uncertainty in inputs and structure into the conclusions. Because resources are finite, the analysis is interpreted against the opportunity cost of displaced alternatives, often summarised by a cost-effectiveness threshold (Drummond et al., 2005; Caro et al., 2012; Hutubessy et al., 2003).
Clinical relevance
These methods underpin health technology assessment and reimbursement decisions in many health systems, so familiarity with them supports critical reading of cost-effectiveness studies. The area describes how economic evidence is produced and judged; it is a reference for methodology and is not a basis for individual clinical or treatment decisions.
Evidence & guidelines
Conduct and reporting are guided by widely used reference works and standards, including the Drummond et al. textbook on methods for economic evaluation, the ISPOR-SMDM Modeling Good Research Practices series, and the CHEERS reporting statement; the WHO-CHOICE framework provides guidance for generalized cost-effectiveness analysis at the population level (Drummond et al., 2005; Caro et al., 2012; Husereau et al., 2013; Hutubessy et al., 2003).
History
Economic evaluation in health grew from cost-benefit analysis in the post-war period and was consolidated as a distinct methodology during the 1970s and 1980s, with successive editions of Drummond and colleagues' textbook codifying the field. Decision-analytic modelling and probabilistic uncertainty analysis became standard from the 1990s onward, and reporting standards such as CHEERS formalised expectations for transparency in the 2010s (Drummond et al., 2005; Husereau et al., 2013).
Debates
- Where should the cost-effectiveness threshold come from?
- Whether the value used to judge cost-effectiveness should reflect willingness to pay or the health forgone (opportunity cost) within a fixed budget is a long-running methodological dispute that affects every reimbursement decision.
Key figures
- Michael Drummond
- Mark Sculpher
- Andrew Briggs
- Karl Claxton
- Tessa Tan-Torres Edejer
Related topics
Seminal works
- drummond-2005
- caro-2012-overview
- husereau-2013-cheers
Frequently asked questions
- What is the difference between cost-effectiveness and cost-utility analysis?
- Both compare costs with health outcomes, but cost-effectiveness analysis measures outcomes in natural units (such as cases prevented), whereas cost-utility analysis uses a preference-based measure such as the quality-adjusted life year, allowing comparison across different conditions.
- Why is opportunity cost central to health economic analysis?
- Because health-care budgets are limited, spending on one intervention means forgoing the health that the same resources could have produced elsewhere; opportunity cost is the framework that makes this trade-off explicit.